<DOC>
	<DOCNO>NCT02637115</DOCNO>
	<brief_summary>Overweight obesity reach worldwide epidemic level . Both overweight obesity characterize comorbidities cardio-metabolic risk factor ( i.e. , insulin resistance , type 2 diabetes , hypertension , dyslipidemia , low-grade inflammation ) represent major public health problem . Therefore , urgent find therapeutic solution target metabolic disorder . Among environmental factor able influence individual susceptibility gain weight develop metabolic disorder associate obesity , evidence show trillion bacteria house gastro-intestinal tract ( i.e , gut microbiota ) influence host metabolism . The investigator recently discover putative interesting microbial candidate , namely Akkermansia muciniphila ( Akk ) . More exactly , find administration Akkermansia muciniphila reduce body weight gain , fat mass gain , glycemia inflammatory marker diet-induced obese mouse . Moreover , overweight/obese patient cardiovascular risk factor subject calorie restriction diet ( calorie restriction diet 6 week additional 6 week weight maintenance ) , high abundance Akkermansia muciniphila associate well cardio-metabolic status patient . The investigator also discover patient Akkermansia muciniphila gut calorie restriction exhibit great improvement glucose homoeostasis , blood lipid body composition calorie restriction . These observation suggest administration Akkermansia muciniphila overweight obese people could interest therapeutic solution . Currently , human study investigate beneficial effect Akkermansia muciniphila administration obesity metabolic disorder . The overall objective study evaluate effect associate administration live heat-killed Akkermansia muciniphila metabolic disorder ( insulin-resistance , type-2 diabetes , dyslipidemia , inflammation ) relate overweight obesity human .</brief_summary>
	<brief_title>Evaluation Effects Associated With Administration Akkermansia Muciniphila Parameters Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Glucose Metabolism Disorders</mesh_term>
	<criteria>Aged 18 70 year old Caucasian Insulin resistance ( base HOMA singlevalue ) BMI 25 50 kg/m² Metabolic syndrome : presence least 3 follow criterion Hypertension ( blood pressure ≥ 130/85 mm Hg antihypertensive treatment ) Hypertriglyceridemia ( triglyceridemia ≥ 150mg/dl ) Low HDLcholesterol ( HDLcholesterol &lt; 40mg/dl male , 50mg/dl female ) Visceral obesity ( waist circumference &gt; 102 cm male , 88cm female ) Fasting hyperglycemia ( fast glycemia ≥ 110mg/dl ) Informed consent sign patient Acute chronic progressive chronic unstabilized disease Alcohol consumption ( 2 glass per day ) Previous bariatric surgery Surgery 3 month prior study surgery plan next 6 month Pregnancy pregnancy plan next 6 month More 30 minute sport 3 time per week Consumption dietary supplement ( omega3 fatty acid , probiotic , prebiotics , plant stanols/sterols ) month prior study Inflammatory bowel disease irritable bowel syndrome Diabetic gastrointestinal autonomic neuropathy ( gastroparesis reduce gastrointestinal motility ) Consumption 30g dietary fiber per day Vegetarian unusual diet Lactose intolerance milk protein allergy Gluten intolerance Medications influence parameter interest ( antidiabetic drug metformin , DPP4 inhibitor , GLP1 receptor agonist , acarbose , hypoglycemic sulfonamide , glinides , thiazolidinediones , SGLT2 inhibitor , insulin , lactulose , consumption antibiotic 2 month prior study , corticosteroid , immunosuppressive agent , statin , fibrate , orlistat , cholestyramine , ezetimibe ) Glycated hemoglobin ( HbA1c ) &gt; 7.5 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Gut microbiota</keyword>
	<keyword>Akkermansia muciniphila</keyword>
</DOC>